Related Experiment Video
Updated: Mar 26, 2026
05:49
Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking
Published on: October 10, 2019
7.1K
Decipher Genomic Classifier Measured on Prostate Biopsy Predicts Metastasis Risk
Eric A Klein1, Zaid Haddad2, Kasra Yousefi2
1Cleveland Clinic, Glickman Urological and Kidney Institute, Cleveland, OH.
Urology
|January 26, 2016
Summary
The Decipher genomic classifier accurately predicts prostate cancer metastasis risk from biopsy samples. This tool can help guide treatment decisions and patient expectations after radical prostatectomy.
Area of Science:
- Oncology
- Genomics
- Prostate Cancer Research
Background:
- Prostate cancer metastasis remains a significant clinical challenge.
- Accurate prediction of metastasis risk is crucial for treatment planning.
- Genomic classifiers offer potential for improved risk stratification.
Purpose of the Study:
- To assess the predictive capability of the Decipher genomic classifier for metastasis in prostate cancer.
- To evaluate Decipher's performance using prostate needle biopsy specimens.
Main Methods:
- Analysis of biopsy specimens from 57 patients treated with radical prostatectomy.
- Utilized Cox multivariable proportional hazards model and survival C-index for performance evaluation.
- Compared Decipher combined with National Comprehensive Cancer Network (NCCN) guidelines against NCCN alone.
Main Results:
- The Decipher plus NCCN model demonstrated a higher C-index (0.88) compared to NCCN alone (0.75).
- Decipher was the sole significant predictor of metastasis on multivariable analysis.
- A 10% increase in Decipher score correlated with a 1.72-fold increased risk of metastasis (P=.02).
Conclusions:
- Biopsy-derived Decipher score effectively predicts 10-year metastasis risk post-radical prostatectomy.
- Preoperative Decipher risk assessment may inform the need for multimodality therapy.
- Further validation in larger cohorts is recommended to confirm findings.
